drugset
drugset / Trial / NCT02301936

Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease

NCT02301936 ↗

Phase 2 Completed 10 enrolled Gilead Sciences
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) administered for 12 or 24 weeks in adults with genotype 1 or 4 hepatitis C virus (HCV) infection with sickle cell disease (SCD).

Timeline

Start
2015-03-02
Primary completion
2016-04-18
Completion
2016-04-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Ledipasvir/Sofosbuvir Unknown 90 mg Oral
Subject Ledipasvir/Sofosbuvir Unknown 400 mg Oral

Indications

hepatitis C virus infection